The use of chelating agents in the treatment of aluminum overload

References

• Alfrey A. C., Mishell J. M., Burks I., Contiguglia S. R., Rudolph H., Lewin E., Holmes J. H. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans. Am. Soc. Artif. Intern. Organs 1972; 18: 257–261
   PubMedGoogle Scholar
• Mahurkar S. D., Meyers L., Cohen J., Kanath R. V., Dunea G. Electroencephalographic and radionuclide studies in dialysis dementia. Kidney Int. 1978; 13: 306–315
   PubMed Web of Science ®Google Scholar
• Rosenbek J. C., McNeil M. R., Lemme M. L., Prescott T. E., Alfrey A. C. Speech and language findings in a chronic hemodialysis patient. J. Speech Hearing Dis. 1975; 40: 245–252
   PubMedGoogle Scholar
• Ackrill P., Ralston A. J., Day J. P. Role of deferrioxamine in the treatment of dialysis encephalopathy. Kidney Int. 1986; 29: S104–S107, suppl 18
   Google Scholar
• Alfrey A. C., LeGendre G. R., Kaehny W. D. The dialysis encephalopathy syndrome: Possible aluminum intoxication. N. Engl. J. Med. 1976; 294: 184–188
   PubMed Web of Science ®Google Scholar
• Tielemans C., Collart F., Wens R., Smeyers-Verbeeke J., Van Hoof I., Dratwa M., Verbelen D. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease. Clin. Nephrol. 1985; 24: 237–241
   PubMed Web of Science ®Google Scholar
• Candy J. M., Klinowski J., Perry R. H., Perry E. K., Fairbairn A., Oakley A. E., Carpenter T. A., Atack J. R., Blessed G., Edwardson J. A. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet 1986; 1: 354–357
   PubMed Web of Science ®Google Scholar
• Crapper D. R., Krishnan S. S., Dalton A. J. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science 1973; 180: 511–513
   PubMed Web of Science ®Google Scholar
• Perl D. P., Brody A. R. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 1980; 208: 297–299
   PubMed Web of Science ®Google Scholar
• McDermott J. R., Smith A. I., Iqbal K., Wisniewski H. M. Brain aluminum in aging and Alzheimer disease. Neurology 1979; 29: 809–814
   PubMed Web of Science ®Google Scholar
• Markesbery W. R., Ehmann W. D., Hossain T. I.M., Alauddin M., Goodin D. T. Instrumental neutron activation analysis of brain aluminum in Alzheimer disease and aging. Ann. Neurol. 1981; 10: 511–516
   PubMed Web of Science ®Google Scholar
• Alfrey A. C., Hegg A., Miller N., Berl T., Berns A. Interrelationship between calcium and aluminum metabolism in dialyzed uremic patients. Miner. Electrolyte Metab. 1979; 2: 81–87
   Google Scholar
• Buchanan M. R.C., Ihle B. U., Dunn C. M. Hemodialysis related osteomalacia: a staining method to demonstrate aluminum. J. Clin. Pathol. 1981; 34: 1352–1354
   PubMed Web of Science ®Google Scholar
• Ott S. M., Maloney N. A., Coburn J. V., Alfrey A. C., Sherrard D. J. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N. Engl. J. Med. 1982; 307: 709–713
   PubMed Web of Science ®Google Scholar
• Pierides A. M., Edwards W. G., Jr, Cullum U. X., Jr, McCall J. T., Ellis H. A. Hemodialysis encephalopathy with osteomalic fractures and muscle weakness. Kidney Int. 1980; 18: 115–124
   PubMed Web of Science ®Google Scholar
• Hodsman A. B., Sherrard D. J., Wong E. G.C., Brickman A. S., Lee D. B.N., Alfrey A. C., Singer F. R., Norman A. V., Coburn J. W. Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Annal. Intern. Med. 1981; 94: 629–637
   PubMed Web of Science ®Google Scholar
• Ellis H. A., McCarthy J. H., Herrington J. Bone aluminum in hemodialyzed patients and in rats injected with aluminum chloride: Relationship to impaired bone mineralization. J. Clin. Pathol. 1979; 32: 832–844
   PubMed Web of Science ®Google Scholar
• Ott S. M., Recker R. R., Coburn J. W., Sherrard D. J. Vitamin D therapy in aluminum-related osteomalacia. Kidney Int. 1983; 23: 107
   Web of Science ®Google Scholar
• Elliott H. L., Mac Dougall A. I., Fell G. S. Aluminum toxicity syndrome. Lancet 1978; 1: 1203
   PubMed Web of Science ®Google Scholar
• Short A. I.K., Winney R. J., Robson J. S. Reversible microcytic hypochromic anemia in dialysis patients due to aluminum intoxication. Proc. EDTA 1980; 17: 226–233
   Google Scholar
• Wills M. R., Savory J. Aluminum poisoning: dialysis encephalopathy, osteomalacia, and anemia. Lancet 1983; 2: 29–34
   PubMed Web of Science ®Google Scholar
• Touam M., Martinez F., Lacour B., Bourdon R., Zingraff J., Di Giulio S., Drüeke T. Aluminum-induced reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin. Nephrol. 1983; 19: 295–298
   PubMed Web of Science ®Google Scholar
• Kaiser L., Schwartz K. A., Burnatowska-Hledin M. A., Mayor G. H. Microcytic anemia secondary to intraperitoneal aluminum in normal and uremic rats. Kidney Int. 1984; 26: 269–274
   PubMed Web of Science ®Google Scholar
• Altmann P., Marsh F., Plowman D., Cunningham J. Aluminum chelation therapy in dialysis patients: evidence for inhibition of hemoglobin synthesis by low levels of aluminum. Lancet 1988; 1: 1012–1015
   PubMed Web of Science ®Google Scholar
• Cannata J. B., Briggs J. D., Junor B. J.R., Fell G. S. Aluminum hydroxide intake: Real risk of aluminum toxicity. Br. Med. J. 1983; 286: 1937–1938
   PubMed Web of Science ®Google Scholar
• Sorenson J. R.J., Campbell I. R., Tepper L. B., Lingg R. D. Aluminum in th environment and human health. Environ. Health Perspect. 1974; 8: 3–95
   PubMedGoogle Scholar
• Yokel R. A., Kostenbauder H. B. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum loaded-rabbit. Toxical. Appl. Pharmacol. 1987; 91: 281–292
   PubMed Web of Science ®Google Scholar
• Adhemar J. P., Laederich J., Jaudon M. C., Masselot J. P., Galli A., Kleinknecht D. Removal of aluminum from patients with dialysis encephalopathy. Lancet 1980; 2: 1311
   PubMed Web of Science ®Google Scholar
• Milliner D. S., Hercz G., Miller J. M., Shinaberger J. H., Nissenson A. R., Coburn J. W. Clearance of aluminum by hemodialysis: Effect of desferrioxamine. Kidney Int. 1986; 29: S100–S103, suppl 18
   Google Scholar
• Kaehny W. D., Alfrey A. C., Holman R. E. Aluminum transfer during hemodialysis. Kidney Int. 1977; 12: 361–365
   PubMed Web of Science ®Google Scholar
• Ackrill P., Day J. P. Desferrioxamine in the treatment of aluminum overload. Clin. Nephrol. 1985; 24: S94–S97, suppl 1
   PubMed Web of Science ®Google Scholar
• Ward M. K., Feest T. G., Ellis H. A., Parkinson I. S., Kern D. N.S., Herrington J., Goode G. L. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne etiological agent, probably aluminum. Lancet 1978; 1: 841–845
   PubMed Web of Science ®Google Scholar
• King S. W., Savory J., Wills M. R. The clinical biochemistry of aluminum. CRC Crit. Rev. Lab. Sci. 1981; 14: 1–20
   Web of Science ®Google Scholar
• Jones M. M. Antagonists for toxic heavy metals. Proc. West Pharmacol. Soc. 1984; 27: 163–167
   PubMedGoogle Scholar
• Jones M. M., Pratt T. H. Therapeutic chelating agents. J. Chem. Educ. 1976; 53: 342–347
   PubMed Web of Science ®Google Scholar
• Aaseth J. Recent advances in the therapy of metal poisoning with chelating agents. Hum. Toxicol. 1983; 2: 252–272
   Google Scholar
• Aposhian H. V. DMSA and DMPS-water soluble antidotes for heavy metal poisoning. Annu. Rev. Pharmacol. Toxicol. 1983; 23: 193–215
   PubMed Web of Science ®Google Scholar
• Andersen O., Nielsen J. B., Svendsen P. Oral cadmium chloride intoxication in mice: Effects of chelation. Toxicology 1988; 52: 65–79
   PubMed Web of Science ®Google Scholar
• Llobet J. M., Colomina M. T., Domingo J. L., Corbella J. Comparison of the antidotal efficacy of polyamincarboxylic acids (CDTA and DTPA) with time after acute zinc poisoning. Vet. Hum. Toxicol. 1989; 31: 25–28
   PubMedGoogle Scholar
• Ortega A., Domingo J. L., Gómez M., Corbella J. Treatment of experimental acute uranium poisoning by chelating agents. Pharmacol. Toxicol. 1989; 64: 247–251
   PubMedGoogle Scholar
• Baker L. R.I., Barnett M. D., Brozovic B., Cattell W. R., Ackrill P., McAlister J., Nimmon C. Hemosiderosis in a patient on regular hemodialysis: Treatment by desferrioxamine. Clin. Nephrol. 1976; 6: 326–328
   PubMedGoogle Scholar
• Pippard M. P., Callender S. T. The management of iron chelation therapy. Br. J. Hematol. 1983; 54: 503–507
   PubMed Web of Science ®Google Scholar
• Stanbaugh G., Gillit D., Holmes A. Indications for and results of long term iron chelation in dialysis hemosiderosis. Am. Soc. Nephrol. Abstracts 1984; 17: 75A
   Google Scholar
• Catsch A., Harmuth-Hoene A. E., Mellor D. P. The Chelation of Heavy Metals, W. G. Levine. Pergamon Press, Oxford 1979
   Google Scholar
• Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. 1964; 119: 758–768
   PubMed Web of Science ®Google Scholar
• Ackrill P., Ralston A. J., Day J. P., Hodge K. C. Successful removal of aluminum from a patient with dialysis encephalopathy. Lancet 1980; 2: 692–693
   PubMed Web of Science ®Google Scholar
• Arze R. S., Parkinson I. S., Cartlidge N. E.F., Britton P., Ward M. K. Reversal of aluminum dialysis encephalopathy after desferrioxamine treatment. Lancet 1981; 2: 1116–1119
   PubMed Web of Science ®Google Scholar
• Pogglitsch H., Petek W., Wanschrinek O., Holzer W. Treatment of early stages of dialysis encephalopathy by aluminum depletion. Lancet 1981; 2: 1344–1346
   PubMed Web of Science ®Google Scholar
• Milne F. J., Sharfe B., Bell P., Meyers A. M. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Clin. Nephrol. 1983; 20: 202–207
   PubMed Web of Science ®Google Scholar
• Malluche H. H., Smith A. J., Abreo K., Faugere M. C. The use of desferrioxamine in the management of aluminum accumulation in bone in patients with renal failure. N. Engl. J. Med. 1984; 311: 140–144
   PubMed Web of Science ®Google Scholar
• Ott S. M., Andress D. L., Nebeker H. G., Milliner D. S., Maloney N. A., Coburn J. W., Sherrard D. J. Changes in bone histology after treatment with desferrioxamine. Kidney Int. 1986; 29: S108–S113, suppl 18
   PubMedGoogle Scholar
• Rapoport J., Chaimovitz C., Abulfil A., Mostovlavsky M., Gazit D., Bab I. Aluminum-related osteomalacia: Clinical and histological improvement following treatment with desferrioxamine (DFO). Isr. J. Med. Sci. 1987; 23: 1242–1246
   PubMedGoogle Scholar
• De la Serna F. J., Praga M., Gilsanz F., Rodicio J. L., Ruilope L. M., Alcazar J. M. Improvement of the erythropoiesis of chronic hemodialysis patients with desferrioxamine. Lancet 1988; 1: 1009–1011
   PubMed Web of Science ®Google Scholar
• Melograna J. M., Yokel R. A. Effect of the chelator desferrioxamine on aluminum elimination in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 1983; 40: 497–509
   PubMedGoogle Scholar
• Melograna J. M., Yokel R. A. Effects of subchronic desferrioxamine infusion on aluminum toxicity in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 1984; 44: 411–422
   PubMedGoogle Scholar
• Swartz R. D. Deferoxamine and aluminum removal. Am. J. Kidney Dis. 1985; 6: 358–364
   PubMed Web of Science ®Google Scholar
• Allain P., Mauras Y., Beaudeau G. L., Hingouet P. Indirect micro-scale method for the determination of desferrioxamine and its aluminum and iron chelated forms in biological samples by atomic absorption spectrometry with electrothermal atomisation. Analyst 1986; 111: 531–533
   PubMed Web of Science ®Google Scholar
• Allain P., Chaleil D., Mauras Y., Beaudeau G., Varin M. C., Poignet J. L., Ciancioni C., Ang K. S., Cam G., Simon P. Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on hemodialysis. Clin. Chim. Acta 1987; 170: 331–338
   PubMed Web of Science ®Google Scholar
• Allain P., Chaleil D., Mauras Y., Varin M. C., Ang K. S., Cam G., Simon P. Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis. Clin. Chim. Acta 1988; 173: 313–316
   PubMed Web of Science ®Google Scholar
• Domingo J. L., Llobet J. M., Gómez M., Corbella J. Acute aluminum intoxication: A study of the efficacy of several antidotal treatments in mice. Res. Commun. Chem. Pathol. Pharmacol. 1986; 53: 93–104
   PubMedGoogle Scholar
• Domingo J. L., Gómez M., Llobet J. M., Corbella J. Comparative effects of several chelating agents on the toxicity, distribution and excretion of aluminum. Hum. Toxicol. 1988; 7: 259–262
   PubMedGoogle Scholar
• Olivieri N. F., Buncic R., Chew E., Gallant T., Harrison R., Keenan N., Logan W., Mitchell D., Ricci G., Skarf B., Taylor M., Freedman M. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N. Engl. J. Med. 1986; 314: 869–873
   PubMed Web of Science ®Google Scholar
• Robins-Browne R. M., Prpic J. K. Effects of deferoxamine on infections with Yersinia enterecolitica. Infect. Immunol. 1985; 47: 774–779
   PubMed Web of Science ®Google Scholar
• Gallant T., Freedman M. H., Vellend H., Francombe V. T. Yersinia sepsis in patients with iron overload treated with deferoxamine. N. Engl. J. Med. 1986; 314: 1643
   PubMed Web of Science ®Google Scholar
• Rahi A. H.S., Hungerford J. L., Ahmed A. I. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br. J. Ophthalmol. 1986; 70: 373–381
   PubMed Web of Science ®Google Scholar
• Davies S. C., Marcus R. E., Hungerford J. L., Miller M. H., Arden G. B., Huehns E. R. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2: 181–184
   PubMed Web of Science ®Google Scholar
• Walker J. A., Sherman R. A., Eisinger R. P. Thrombocytopenia associated with intravenous desferrioxamine. Am. J. Kidney Dis. 1985; 6: 254–256
   PubMed Web of Science ®Google Scholar
• Domingo J. L., Gómez M., Llobet J. M., Corbella J. Citric, malic and succinic acids as possible alternatives to deferoxamine in aluminum toxicity. Clin. Toxicol. 1988; 26: 67–79
   Web of Science ®Google Scholar
• Rajan K. S., Mainer S., Rajan N. L., Davis J. M. Studies on the chelation of aluminum for neurobiological application. J. Inorg. Chem. 1981; 14: 339–350
   PubMed Web of Science ®Google Scholar
• Jackson G. E. Studies on the chelation of aluminum for biological application. Part 1. Citric acid. S. Afr. J. Chem. 1982; 35: 89–92
   Google Scholar
• Jackson G. E., Cosgrove A. Studies on the chelation of aluminum for biological application. Part 2. Oxalic, malonic and succinic acids. S. Afr. J. Chem. 1982; 35: 93–95
   Google Scholar
• Jons O., Johansen E. S. Formation of aluminum and zinc complexes with picolinic acid. A potentiometric investigation. Inorg. Chim. Acta 1988; 151: 129–132
   Web of Science ®Google Scholar
• Llobet J. M., Domingo J. L., Gómez M., Tomás J. M., Corbella J. Acute toxicity studies of aluminum compounds: Antidotal efficacy of several chelating agents. Pharmacol. Toxicol. 1987; 60: 280–283
   PubMedGoogle Scholar
• Hewitt C. D., Poole C. L., Westervelt F. B., Jr, Savory J., Wills M. R. Risks of simultaneous therapy with oral aluminum and citrate compounds. Lancet 1988; 2: 849
   PubMed Web of Science ®Google Scholar
• Slanina P., Falkeborn Y., Frech W., Cedergren A. Aluminum concentrations in the brain and bone of rats fed citric acid, aluminum citrate or aluminum hydroxide. Food Chem. Toxicol. 1984; 22: 391–397
   PubMed Web of Science ®Google Scholar
• Slanina P., Frech W., Bernhardson A., Cedergren A., Mattson P. Influence of dietary factors on aluminum absorption and retention in the brain and bone of rats. Acta Pharmacol. Toxicol. 1985; 56: 331–336
   PubMedGoogle Scholar
• Fulton B., Jaw S., Jeffery E. H. Bioavailability of aluminum from drinking water. Fundam. Appl. Toxicol. 1989; 12: 144–150
   PubMedGoogle Scholar
• Slanina P., Frech W., Ekström L. G., Loof L., Storach S., Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin. Chem. 1986; 32: 539–541
   PubMed Web of Science ®Google Scholar
• Bakir A. H., Hryhorczuk D. O., Berman E., Dunea G. Acute fatal hyperaluminemia encephalopathy in undialyzed and recently dialyzed uremic patients. Trans. Am. Soc. Artif. Intern. Organs 1986; 32: 171–176
   Google Scholar
• Kirschbaum B. B., Schoolwerth A. C. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am. J. Med. Sci. 1989; 297: 9–11
   PubMed Web of Science ®Google Scholar
• Domingo J. L., Gómez M., Llobet J. M., Corbella J. Parenteral citric acid for aluminum intoxication. Lancet 1988; 2: 1362–1363
   PubMed Web of Science ®Google Scholar